The 2012 focused update of the ESC Guidelines for the management of atrial fibrillation mainly covers the fields of anticoagulation, antiarrhythmic drug therapy, and catheter ablation. As for anticoagulation, the CHADSVASc-and the HAS-BLED-Scores for risk stratification as well as the new anticoagulants are fully introduced. Vernakalant and Dronedaron are two new antiarrhythmic drugs whose indications and contraindications are covered in the new guidelines. Finally, the role of catheter ablation as a treatment strategy for atrial fibrillation is further emphasized.
分享
引用
